Cannabis Technologies Inc. Changes Name to InMed Pharmaceuticals Inc.
October 16, 2014 (Source: Marketwired) — Cannabis Technologies Inc. (the Company) (CSE:CAN)(OTCQB:CANLF) is pleased to announce a name change to InMed Pharmaceuticals Inc. (“InMed”). InMed will trade under the new ticker symbol “CSE: IN”. The change will take effect and will trade on the Canadian Securities Exchange on Tuesday, October 21, 2014. The Company is in the process of effecting the name change and new symbol with the OTC Markets and FINRA. The Company expects to complete this process shortly and will provide a further update. The Company will continue to trade as “CANLF” until such time.
Craig Schneider, President and CEO states, “The new name and identity was affected to better position the company within the Life Science Sector and towards a much broader investor base both in North America and abroad. We believe the new name and identity more accurately reflects the Company’s business model and direction.”
About InMed Pharmaceuticals Inc.
InMed is a clinical stage biopharmaceutical company that specializes in developing cannabis based therapies through the Research and Development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. The company’s Proprietary Platform Technology, Product pipeline and accelerated drug discovery/commercialization development pathway are the fundamental value drivers of the company.
ON BEHALF OF THE BOARD
InMed Pharmaceuticals Inc.
Get our daily investorintel update
Craig Schneider, President and Chief Executive Officer
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Raj Shah has professional experience working for over a half a dozen years at financial firms such as Merrill Lynch and First Allied Securities Inc., ... <Read more about Raj Shah>